Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814441 | 0.80 | NOTUM (0.44) | NOTUMLRRK2MAPK14PTPN11L3MBTL1 | |
| SCHEMBL14814035 | 0.74 | MAPK14 (0.38) | NOTUMLRRK2MAPK14PTPN11PDPK1 | |
| SCHEMBL14814732 | 0.71 | NOTUM (0.49) | NOTUMMAPK14PTPN11GAAMEN1 | |
| SCHEMBL2634245 | 0.70 | GAA (0.37) | LRRK2MAPK14GAAKDM4EPDPK1 | |
| SCHEMBL12467712 | 0.69 | MEN1 (0.39) | NOTUMPTPN11GAAPDPK1MEN1 | |
| SCHEMBL8863558 | 0.67 | NOTUM (0.45) | NOTUMLRRK2PTPN11GAAKDM4E | |
| SCHEMBL29484715 | 0.67 | NOTUM (0.45) | NOTUMLRRK2PTPN11GAAKDM4E | |
| SCHEMBL7260405 | 0.66 | JAK2 (0.51) | GAAKDM4EPDPK1CYP3A4MEN1 | |
| SCHEMBL2660889 | 0.64 | GAA (0.56) | LRRK2MAPK14GAAKDM4EPDPK1 | |
| SCHEMBL3640606 | 0.64 | PDPK1 (0.43) | GAAKDM4EPDPK1CYP3A4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668184-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PF MEDICAMENT (FR) | 2018-01-10 | — | — | EP | disclosed |
| EP-2877176-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK | PF MEDICAMENT (FR) | 2017-04-26 | — | — | EP | disclosed |
| EP-2877177-B1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PF MEDICAMENT (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-9428510-B2 | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing Trk | PIERRE FABRE MEDICAMENT (FR) | 2016-08-30 | — | — | US | disclosed |
| US-9381195-B2 | Derivatives of azaindazole or diazaindazole type for treating pain | PIERRE FABRE MEDICAMENT (FR) | 2016-07-05 | — | — | US | disclosed |
| US-20150266880-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk | PIERRE FABRE MEDICAMENT (FR) | 2015-09-24 | — | — | US | disclosed |
| US-20150190394-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | PIERRE FABRE MEDICAMENT (FR) | 2015-07-09 | — | — | US | disclosed |
| US-8883821-B2 | Substituted pyrazolo[3,4-b]pyridines as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2014-11-11 | — | — | US | disclosed |
| EP-2689779-A1 | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| EP-2689778-A1 | Derivatives of azaindoles or diazaindoles for treating pain | PIERRE FABRE MEDICAMENT (FR) | 2014-01-29 | — | — | EP | disclosed |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | PIERRE FABRE MEDICAMENT (FR) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266880-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING Trk | TTK, NTRK1, NTRK3 | NOTUM 4442/4885LRRK2 1899/4885MAPK14 782/4885 |
| US-20130085144-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT | MAP2K5, MAP2K2, MAP2K3 | NOTUM 371/4885LRRK2 589/4885MAPK14 151/4885 |
| US-20150190394-A1 | DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN | SCN3A, ACHE, QDPR | NOTUM 2157/4885LRRK2 4349/4885MAPK14 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.